Register for our free email digests:
Eisai Co., Ltd.
https://www.eisai.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
Nutrition Market Results: Nestle Health 'Bullish', Abbott Adult Products Lead, USANA Ups Guidance
USANA raises guidance on strong Asian sales; nutritional sales boost Nestle’s overall results; and Abbott Nutrition US sales up 3.7%.
India Q2 Preview: Glenmark, Cipla Emerge Stronger
With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.
APACMed: Johnson & Johnson On Using ‘Big’ For Good In The COVID-19 Challenge
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
Coronavirus Update: Human Vaccine Challenge Study Gains UK Backing
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Other Names / Subsidiaries
-
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.